for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Fortress Biotech says FDA has granted CEVA101 RMAT for treatment of traumatic brain injury

Nov 8 (Reuters) - Fortress Biotech Inc:

* Fortress Biotech announces Cellvation’s CEVA101 granted FDA regenerative medicine advanced therapy designation for the treatment of traumatic brain injury

* Fortress Biotech Inc - CEVA101 is currently being assessed in phase 2 clinical trials for severe TBI in children and adults Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up